Abstract
Results of a study of rates of acute kidney injury (AKI) in pediatric patients treated with vancomycin plus piperacillin-tazobactam or vancomycin plus alternative antipseudomonal β-lactams (APBLs) are reported. A retrospective, single-center cohort study was performed. Pediatric patients were included in the study cohort if they received combination therapy for at least 48 hours, had documented baseline and follow-up serum creatinine levels, and had a documented serum vancomycin trough concentration. The primary outcome was the frequency of AKI, defined as a 50% or greater increase in serum creatinine concentration from baseline or an increase of at least 0.5 mg/dL from baseline. The secondary outcome was time to AKI onset. A total of 474 patients were included. Among 100 patients who received vancomycin plus piperacillin-tazobactam, the rate of AKI was higher than the rate in the group treated with vancomycin plus alternative APBLs (27% versus 7%, p < 0.0001). The median time to AKI onset was shorter in the piperacillin-tazobactam group versus the alternative APBL group (3.8 versus 7.9 days, p = 0.0065). Patients who were administered piperacillin-tazobactam were almost 6 times as likely to develop AKI (odds ratio [OR], 5.955;...Continue Reading
References
Jul 3, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael J RybakDonald P Levine
Jan 28, 2010·The American Journal of Medicine·Kathleen A HazlewoodRonald G Hall
Mar 14, 2012·European Journal of Clinical Pharmacology·Sepideh ElyasiAmirhooshang Mohammadpour
Apr 5, 2014·Pharmacotherapy·Calvin J MeaneyMona G Tsoukleris
Apr 23, 2014·Pharmacotherapy·Diane M GomesChristopher A Jankowski
May 24, 2014·Pharmacotherapy·Lindsey D Burgess, Richard H Drew
Jul 1, 2015·Antimicrobial Agents and Chemotherapy·Jesse D SuttonJason M Pogue
Jul 15, 2015·The Annals of Pharmacotherapy·Chad A KnodererAmy C Wilson
Feb 3, 2016·Clinical Therapeutics·Kristen E FoderoKari A Mergenhagen
Feb 26, 2016·Journal of Pharmacy Practice·Vincent PeykoHenry Cohen
Nov 3, 2016·Pharmacotherapy·Christopher A GiulianoPramodini B Kale-Pradhan
Dec 18, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bhagyashri NavalkeleKeith S Kaye
Mar 28, 2017·Antimicrobial Agents and Chemotherapy·W Cliff RutterDavid S Burgess
May 20, 2017·International Journal of Antimicrobial Agents·Nakyung JeonAlmut G Winterstein
Oct 4, 2017·JAMA Pediatrics·Kevin J DownesTheoklis E Zaoutis
Oct 25, 2017·BMJ Open·Peng LiJie Teng
Jan 16, 2019·International Journal of Pediatrics·Mohammed Al NuhaitRami T Bustami
Citations
Oct 9, 2019·Antimicrobial Agents and Chemotherapy·Markos KalligerosEleftherios Mylonakis
Mar 31, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·I BellosD N Perrea
Jul 9, 2021·Paediatric Drugs·Emma M Tillman, Jennifer L Goldman